文献速递颈动脉与弓上血管

覆膜支架在经颈动脉血运重建术中的选择性应用初探

Initial Results of Selected Use of Covered Stents in Transcarotid Artery Revascularization.
PubMed 文献 · Ann Vasc Surg · 2020-05-16

结果显示无围术期或30天缺血事件,所有支架在随访期间保持通畅,患者均无症状。覆膜支架在特定患者中安全有效,但需进一步研究。

要点

  • 覆膜支架TCAR在6例高危颈动脉病变患者中无围术期及30天缺血事件。
  • 随访期间所有支架保持通畅,患者均无症状。
  • 覆膜支架可能减少斑块突出和支架内再狭窄,但需进一步验证。

核心结论

  • 覆膜支架用于TCAR在需要颈动脉干预的特定患者中安全有效。
  • 覆膜支架有潜力减少斑块突出和支架内再狭窄导致的长期缺血事件。
  • 需要进一步研究器械设计或临床评估。

研究设计与样本

  • 手术由同一术者在2家机构完成。
  • 共纳入6例患者,5男1女,平均年龄70.8±4.6岁。
  • 适应证包括严重无症状或症状性颈动脉狭窄且为高风险病变(病变长度≥2 cm和/或>50%为软斑块或出血性颈动脉假性动脉瘤)。
  • 所有患者使用Gore Viabahn覆膜支架。

主要发现

  • 围术期及术后30天无缺血事件。
  • 随访期间(平均3.4个月,范围1.4-6.9个月)所有6例支架在双功超声下保持通畅。
  • 所有患者在临床随访中均无症状。

关键数值与推荐

  • 适应证包括4例无症状>70%颈动脉狭窄、1例TIA样症状且>70%狭窄、1例出血性颈动脉假性动脉瘤。
  • 术后所有患者服用氯吡格雷3个月,之后改为阿司匹林,除非另有指示。

临床怎么用

  • 对于高风险颈动脉病变患者,可考虑使用覆膜支架行TCAR以减少斑块突出和支架内再狭窄风险。
  • 术后需短期双联抗血小板治疗(氯吡格雷3个月后改为阿司匹林)。
  • 需密切随访支架通畅性和临床症状。

局限性

  • 样本量小(仅6例),随访时间短(平均3.4个月)。
  • 回顾性研究设计,非随机对照。
  • 单术者经验,可能影响推广性。
  • 缺乏与未覆膜支架的直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcarotid artery revascularization (TCAR) is a novel, hybrid approach to treating carotid disease in the treatment of stroke and stroke prevention. Early results of this hybrid approach to carotid stenting using flow reversal have been promising, with reported stroke rates around 1-2.8%.1,2 Currently, carotid stenting, regardless of approach, is performed with uncovered stents, which incurs the risk of plaque protrusion through the stent and in-stent restenosis. Overall, plaque protrusion is a rare event, with a reported incidence of 2.8% on angiography, but it is associated a high rate of ischemic complications (up to 66.7%).3 The use of covered stents could eliminate the risk of plaque protrusion and therefore short to midterm embolic phenomenon during the remodeling process. It also may improve rates of in-stent restenosis as it is a fully covered stent. Adoption of this technique has the potential to further improve the safety, efficacy, and durability of TCAR. METHODS: We performed a retrospective review of a prospectively maintained database of patients undergoing TCAR with covered stents between September 2018 and December 2019. Procedures were performed by the same operator at 2 separate institutions. Indications included severe asymptomatic or symptomatic carotid stenosis with high-risk lesions defined as lesions 2 cm lesions or longer and/or >50% of the lesion containing soft plaque or bleeding carotid pseudoaneurysm. Our primary outcomes included periprocedural and 30-day stroke rates. Secondary outcomes included stent patency and other procedure-related complications. All patients were maintained on clopidogrel postprocedure for 3 months and then transitioned to aspirin, unless otherwise indicated. RESULTS: A total of 6 patients underwent TCAR with covered stent angioplasty during this time period. Patient demographics included 5 males and 1 female, with an average age of 70.8 ± 4.6 years. Indications for stenting included 4 patients with asymptomatic >70% carotid stenosis and 1 patient with transient ischemic attack-like symptoms and >70% stenosis, and 1 patient with bleeding carotid pseudoaneurysm. Gore Viabahn covered stents were used in all patients. There were no periprocedural or postprocedural ischemic events at 30 days. All 6 stents remained patent at follow-up on duplex ultrasound, and all patients remained asymptomatic on clinical follow-up (average 3.4 [1.4-6.9] months). CONCLUSIONS: The use of covered stents for TCAR appears to be a safe and effective in select patients requiring carotid intervention. It holds the potential to decrease ischemic events from plaque protrusion and in-stent restenosis in the long-term. Further investigation in device design or clinical evaluation is warranted.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Flynn S, Roderick E, Lane J, et al. Initial Results of Selected Use of Covered Stents in Transcarotid Artery Revascularization. Ann Vasc Surg. 2020. PMID: 32428639. doi:10.1016/j.avsg.2020.04.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。